Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials

References

• Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15:736–47.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol. 2012;19:672–80.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014;215:82–6.
   PubMed Web of Science ®Google Scholar
• Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622–7.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–71.
   PubMed Web of Science ®Google Scholar
• Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16:1277–83.
   PubMed Web of Science ®Google Scholar
• von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer. 2013;13:426.
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–44.
   PubMed Web of Science ®Google Scholar
• Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011;73:598–603.
   PubMed Web of Science ®Google Scholar
• Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816–28.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31:550–61.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012;12:132–7.
   PubMed Web of Science ®Google Scholar
• Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012;259:436–47.
   PubMed Web of Science ®Google Scholar
• Hauser W, Bartram C, Bartram-Wunn E, Tolle T. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain. 2012;28:437–51.
   PubMed Web of Science ®Google Scholar
• Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur J Neurol. 2013;20:527–33.
   PubMed Web of Science ®Google Scholar
• Zis P, Mitsikostas DD. Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials. J Neurol Sci. 2015;355:94–100.
   PubMed Web of Science ®Google Scholar
• Zis P, Shafiq F, Mitsikostas DD. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials. Seizure. 2017;45:95–9.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Cincotta M, Loiacono G, Verrotti A. Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. J Neurol. 2015;262:501–15.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. New York: John Wiley & Sons; 2011.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH, 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843–8.
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583–6.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol. 1998;55:93–6.
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology. 1997;49:1621–30.
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology. 1996;47:1383–8.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology. 1996;46:1244–9.
   PubMed Web of Science ®Google Scholar
• Miller RG, Shepherd R, Dao H, Khramstov A, Mendoza M, Graves J, et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord. 1996;6:101–4.
   PubMed Web of Science ®Google Scholar
• Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS study group. Ann Neurol. 1996;39:256–60.
   PubMed Web of Science ®Google Scholar
• Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group. Neurology. 1993;43:2466–70.
   PubMed Web of Science ®Google Scholar
• Baumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med. 2014;107:14–21.
   PubMed Web of Science ®Google Scholar
• Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain. 1996;64:535–43.
   PubMed Web of Science ®Google Scholar